Status:
UNKNOWN
Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis
Lead Sponsor:
Peking University Cancer Hospital & Institute
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Gastric Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To investigate the efficacy of capecitabine combined with paclitaxel as neoadjuvant chemotherapy for gastric cancer with liver metastasis only
Detailed Description
Patients with advanced or metastatic gastric cancer have a poor prognosis. The optimal treatment of gastric cancer with liver metastases without other distant metastases remains a matter for debate an...
Eligibility Criteria
Inclusion
- Ambulatory males or females, aged no less than 18 years.
- ECOG performance status: 0-1.
- Histologically confirmed gastric adeno-carcinoma.
- Radiologically confirmed liver metastasis without other distant metastasis.
- No serious concomitant medical illnesses
- Life expectancy more than 3 months
- Be willing and able to comply with the protocol for the duration of the study
- No Prior treatment for metastatic disease
- Give signed informed consent
Exclusion
- not fit for the inclusion criteria
- not able to comply with the protocol
- with high risks which may compromise the benefit of proposed regimen
- Active (significant or uncontrolled) gastrointestinal bleeding
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2013
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01167049
Start Date
August 1 2009
End Date
December 1 2013
Last Update
July 22 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100036